Printer Friendly

Celox Labs announces formation of Protide Pharmaceuticals.

CELOX Laboratories, Inc., St. Paul, MN, announced it has formed Protide Pharmaceuticals, Inc., a wholly owned subsidiary. The new company will be responsible for the further development of ViaStem and other bone marrow transplant products. The company says ViaStem was discovered to improve the ultra low temperature storage of stem cells from bone marrow, peripheral blood and umbilical cord blood while a patient receives intensive chemotherapy or radiation treatment for certain cancers, blood disorders and serious genetic disorders.

The company also says ViaStem may improve the transfusion of these critical cells which are responsible for producing white blood cells, red blood cells and platelets. Protide will continue to collaborate with the University of Minnesota to complete the preclinical studies of ViaStem.

Contact: David Tess - (651) 730-1500
COPYRIGHT 1999 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Celox Labs announces formation of Protide Pharmaceuticals.
Publication:Transplant News
Geographic Code:1USA
Date:Mar 10, 1999
Previous Article:CryoLife receives CE mark for international distribution of new bioglue delivery system.
Next Article:Aastrom Biosciences receives CE mark for cord blood kit.

Related Articles
Court issues approval of Nanophase's settlement.
High-speed CELOX: slick, eye-catching endload cartoner from Kliklok-Woodman.
McVitie's Jaffa cakes.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters